Pipeline
| Asset | Modality / Target | Regimen | Indication | Discovery | Pre-Clinical | FIH | POC | Pivotal | Status |
|---|---|---|---|---|---|---|---|---|---|
| IN10018 | Small molecular FAK inhibitor | + PLD |
Platinum Resistant Ovarian Cancer |
|
Pivotal study initiated in 2022 | ||||
| + MEKi |
RAS-mu Tumor |
|
PoC to be completed in 2022 | ||||||
| Regimen undisclosed |
PROC, TNBC, HNSCC and Other PLD Indicated Cancers |
|
PoC expected in 2023 | ||||||
| + KRASG12C inhibitor |
KRAS G12C-mu Solid Tumor |
|
PoC expected in 2023 | ||||||
|
+ IO bispecific |
PDAC |
|
CTP approved Q3 2022 | ||||||
| 3rd EGFR TKI |
EGFR-mu NSCLC |
|
PoC to be initiated in 2022 | ||||||
| IN30705 | ADC Targeting FAP | Mono / Combo | Solid Tumor |
|
CTP expected Q4 2022 | ||||
| INES103 | Antibody Target undisclosed | Combo | Solid Tumor |
|
CTP expected Q4 2022 | ||||
| IN30718 | ADC Target undisclosed | Mono | Solid Tumor |
|
PCC nominated in 2023 | ||||
| IN20019 | Small molecular Target undisclosed | Mono | Solid Tumor |
|
PCC nominated in 2023 | ||||
IN10018
IN10018 is a highly potent and selective inhibitor of the focal adhesion kinase (FAK). Anti-tumor activities of IN10018 have been demonstrated in multiple animal models for human cancers. More than 250 patients have been dosed and IN10018 has showed its safety and promising efficacy signal in platinum ovarian cancer and NRAS melanoma.
IN30705
IN30705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment.
INES103
INES103 is an injectable recombinant humanized VHH (single variable domain of heavy chain, VHH)-Fc fusion protein against tumor associate macrophage（TAM）related target, to be administered for treatment of advanced or metastatic solid tumor and hematological malignancies. INES103 is designed to improve tissue penetration against solid tumors.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us：
CopyRight © 2022 InxMed All Rights Reserved.